Home > Haematology > EHA 2021 > Lymphoma > Immuno-oncology agents are effective in treating classic Hodgkin’s lymphoma

Immuno-oncology agents are effective in treating classic Hodgkin’s lymphoma

Presented By
Dr Marc André, Centre Hospitalier Universitaire UCL Namur, Belgium
Conference
EHA 2021
Trial
CheckMate 205; KEYNOTE-087
Checkpoint inhibitors are effective and well tolerated in patients with refractory or relapsing (r/r) Hodgkin’s lymphoma. Several clinical trials also showed encouraging outcomes in patients with previously untreated, unfavourable Hodgkin’s lymphoma. Several immuno-oncology agents are being developed for the treatment of classic Hodgkin’s lymphoma (cHL). Dr Marc André (Centre Hospitalier Universitaire UCL Namur, Belgium) discussed their use in r/r disease post-brentuximab vedotin/autologous haematopoietic stem cell transplantation (ASCT) and pre-ASCT, as well as in first-line treatment of advanced and localised cHL [1]. Immuno-oncology agents as first-line treatment The single-arm, phase 2 CheckMate 205 study (NCT02181738) included a cohort of adults with newly diagnosed, untreated, advanced-sta...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on